PECAM1 and renal cell carcinoma: Dornbusch et al. showed that in metastatic RCC treated with sunitinib, high CD31 expression compared to low CD31 in the primary tumour was associated with better sunitinib response [49], in line with our results of the association of high CD31 with high clinical benefit rate.